

Attorney Docket No. P67214US0
Application Serial. No. 09/926,442

Amendments to the claims:

This listing of claims will replace all prior versions, and listings, of claims in the application:

Listing of claims:

Claims 1-26 (cancelled)

27. (New) A method for diagnosing or prognosing Alzheimer's disease in a subject, or determining whether a subject is at increased risk of developing Alzheimer's disease, comprising:
- determining a level, or an activity, or both said level and said activity, of nerve growth factor in a sample taken from cerebrospinal fluid of said subject; and
- comparing said level, or said activity, or both said level and said activity to a reference value representing a known disease or health status;
- wherein an increase in said level, or a varied activity, or both an increase in said level and a varied activity of nerve growth factor in said cerebrospinal fluid from said subject relative to said reference value representing a known health status indicates a diagnosis, or prognosis, or increased risk of Alzheimer's disease in said subject.
28. (New) A method of monitoring progression of Alzheimer's disease in a subject, comprising:
- determining a level, or an activity, or both said level and said activity, of nerve growth factor in a sample taken from cerebrospinal fluid of said subject; and
- comparing said level, or said activity, or both said level and said activity to a reference value representing a known disease or health status;

Attorney Docket No. P67214US0
Application Serial. No. 09/926,442

wherein an increase in said level, or a varied activity, or both an increase in said level and a varied activity of nerve growth factor in said cerebrospinal fluid from said subject relative to said reference value representing a known health status indicates a diagnosis, or prognosis, or increased risk of Alzheimer's disease in said subject.

29. (New) Use of the method according to claim 36 for evaluating a treatment for Alzheimer's disease.
30. (New) The method according to claim 27, wherein a level of nerve growth factor ≥ 4 pg/ml in said cerebrospinal fluid indicates a diagnosis, or prognosis, or increased risk of Alzheimer's disease in said subject.
31. (New) The method according to claim 30, wherein a level of nerve growth factor in the range from 4 pg/ml to 25 pg/ml in said cerebrospinal fluid indicates a diagnosis, or prognosis, or increased risk of Alzheimer's disease in said subject.
32. (New) The method according to claim 30, wherein a level of nerve growth factor in the range from 4 pg/ml to 14 pg/ml in said cerebrospinal fluid indicates a diagnosis, or prognosis, or increased risk of Alzheimer's disease in said subject.
33. (New) The method according to claim 27, wherein said subject is a human.
34. (New) The method according to claim 27, wherein nerve growth is detected using an immunoassay, bioassay, and/or binding assay.
35. (New) The method according to claim 27, further comprising repeating said determining step for a series of samples taken from said subject over a period of time and comparing a level

Attorney Docket No. P67214US0
Application Serial. No. 09/926,442

and/or an activity of nerve growth factor in said sample with a level and/or an activity in said series of samples.

36. (New) The method according to claim 35, wherein said subject receives a therapeutic treatment for Alzheimer's disease prior to taking one or more of said samples in said series.
37. (New) The method according to claim 36, wherein said level and/or activity in said samples is determined before and after said treatment of said subject.
38. (New) The method according to claim 27, further comprising:
determining a level, or an activity, or both said level and said activity of a further neurotrophin in a sample taken from cerebrospinal fluid of said subject; and
comparing said level, or said activity, or both said level and said activity to a reference value representing a known disease or health status;
wherein a varied level, or activity, or both said level and said activity of said further neurotrophin in said cerebrospinal fluid from said subject relative to said reference value representing a known health status indicates a diagnosis, or prognosis, or increased risk of Alzheimer's disease in said subject.
39. (New) The method according to claim 38 wherein said neurotrophin is neurotrophin-3.
40. (New) The method according to claim 39 wherein a level of neurotrophin-3 ≥ 15 pg/ml in said cerebrospinal fluid indicates a diagnosis, or prognosis, or increased risk of Alzheimer's disease in said subject.

Attorney Docket No. P67214US0
Application Serial No. 09/926,442

41. (New) A kit for diagnosis, prognosis, or determination of increased risk of developing Alzheimer's disease in a subject, said kit comprising:
- a) at least one reagent that detects nerve growth; and
 - b) instructions for diagnosing, or prognosing or determining increased risk of developing Alzheimer's disease by
 - i) detecting a level, or an activity, or both said level and said activity of nerve growth factor in a sample taken from cerebrospinal fluid of said subject; and
 - ii) diagnosing, or prognosing, or determining whether said subject is at increased risk of developing Alzheimer's disease,
- wherein
- an increase in said level, or a varied activity, or both said increase in said level and said varied activity of nerve growth factor compared to a reference value representing a known health status or
 - a level, or an activity, or both said level and said activity, of nerve growth factor similar or equal to a reference value representing a known disease status
- indicates a diagnosis, or prognosis, or increased risk of developing Alzheimer's disease.
42. (New) The kit according to claim 41, wherein a level of nerve growth factor ≥ 4 pg/ml in said cerebrospinal fluid indicates a diagnosis, or prognosis, or increased risk of Alzheimer's disease in said subject.

Attorney Docket No. P67214US0
Application Serial. No. 09/926,442

43. (New) The kit according to claim 42 wherein a level of nerve growth factor in the range from 4 pg/ml to 25 pg/ml in said cerebrospinal fluid indicates a diagnosis, or prognosis, or increased risk of Alzheimer's disease in said subject.
44. (New) The kit according to claim 42 wherein a level of nerve growth factor in the range from 4 pg/ml to 14 pg/ml in said cerebrospinal fluid indicates a diagnosis, or prognosis, or increased risk of Alzheimer's disease in said subject.
45. (New) The kit according to claim 41 further comprising:
- a) at least one reagent which detects a further neurotrophin; and
 - b) instructions for diagnosing, or prognosing Alzheimer's disease, or determining increased risk of developing Alzheimer's disease by
 - i) detecting a level, or an activity, or both said level and said activity, of said further neurotrophin in a sample taken from cerebrospinal fluid of said subject; and
 - ii) diagnosing, or prognosing, or determining whether said subject is at increased risk of developing Alzheimer's disease,
- wherein
- a varied level or activity, or both said level and said activity, of said further neurotrophin compared to a reference value representing a known health status or a level, or an activity, or both said level and said activity, of said further neurotrophin similar or equal to a reference value representing a known disease status indicates a diagnosis, or prognosis, or increased risk of Alzheimer's disease in said subject.

Attorney Docket No. P67214US0
Application Serial. No. 09/926,442

46. (New) The kit according to claim 45 wherein said neurotrophin is neurotrophin-3.
47. (New) The kit according to claim 46 wherein a level of neurotrophin-3 ≥ 1.5 pg/ml in said cerebrospinal fluid indicates a diagnosis, or prognosis, or increased risk of Alzheimer's disease in said subject.
48. (New) The kit according to claim 41 for use in monitoring a progression of Alzheimer's disease in a subject.
49. (New) The kit according to claim 41 for use in monitoring the success or failure of a therapeutic treatment of a subject for Alzheimer's disease.